SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Antony B. Friedman, Miles P. Sparrow, Peter R. Gibson, The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders, International Journal of Rheumatic Diseases, 2014, 17, 2
  2. 2
    Bevra H. Hahn, Jennifer K. King, The Autoimmune Diseases, 2014,

    CrossRef

  3. 3
    Alejandro Díaz-Borjón, Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis, Drugs & Aging, 2009, 26, 4, 273

    CrossRef

  4. 4
    Gianfranco Ferraccioli, Maria De Santis, Barbara Tolusso, Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology, Pharmacogenomics, 2004, 5, 8, 1107

    CrossRef

  5. 5
    Guidelines for the management of rheumatoid arthritis: 2002 Update , Arthritis & Rheumatism, 2002, 46, 2
  6. 6
    John P. Case, Old and New Drugs Used in Rheumatoid Arthritis: A Historical Perspective, American Journal of Therapeutics, 2001, 8, 2, 123

    CrossRef

  7. 7
    Julietta C.T. Lee, Dafna D. Gladman, Catherine T. Schentag, Richard J. Cook, The Long-Term Use of Azathioprine in Patients with Psoriatic Arthritis, JCR: Journal of Clinical Rheumatology, 2001, 7, 3, 160

    CrossRef

  8. 8
    Christopher S. George, Alan E. Lichtin, HEMATOLOGIC COMPLICATIONS OF RHEUMATIC DISEASE THERAPIES, Rheumatic Disease Clinics of North America, 1997, 23, 2, 425

    CrossRef

  9. 9
    Michael M. Ward, Assessing the relative sensitivity to change of rheumatoid arthritis activity measures: Is the type of treatment an important third variable?, Journal of Clinical Epidemiology, 1996, 49, 10, 1161

    CrossRef

  10. 10
    S. ten Wolde, F.C. Breedveld, B.A.C. Dijkmans, J. Hermans, J.P. Vandenbroucke, M.A.F.J. van de Laar, H.M. Markusse, M. Janssen, H.R. van den Brink, Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis, The Lancet, 1996, 347, 8998, 347

    CrossRef

  11. 11
    Richard M. Pope, Rheumatoid arthritis: Pathogenesis and early recognition, The American Journal of Medicine, 1996, 100, 2, 3S

    CrossRef

  12. 12
    William S. Wilke, Joseph M. Cash, The Use of Slower-Acting (Class III) Symptom-Modifying Antirheumatic Drugs in Rheumatoid Arthritis, Clinical Immunotherapeutics, 1996, 5, 4, 309

    CrossRef

  13. 13
    Michael J. Ahern, Geetha Chandran, Category III Symptom-Modifying Antirheumatic Drugs, Clinical Immunotherapeutics, 1995, 3, 3, 196

    CrossRef

  14. 14
    Alastair J.J. Wood, Joseph M. Cash, John H. Klippel, Second-Line Drug Therapy for Rheumatoid Arthritis, New England Journal of Medicine, 1994, 330, 19, 1368

    CrossRef

  15. 15
    Peter T. Dawes, Deborah P.M. Symmons, Short-term effects of antirheumatic drugs, Baillière's Clinical Rheumatology, 1992, 6, 1, 117

    CrossRef

  16. 16
    David T. Felson, Jennifer J. Anderson, Robert F. Meenan, Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials, Arthritis & Rheumatism, 1992, 35, 10
  17. 17
    Pnina Langevitz, Lyn Maguire, Murray Urowitz, Accelerated nodulosis during azathioprine therapy, Arthritis & Rheumatism, 1991, 34, 1
  18. 18
    Maurice E. C. Jeurissen, Agnes M. Th. Boerbooms, Levinus B. A. Van De Putte, Wim H. Doesburg, Jan Mulder, Johannes J. Rasker, Marijn W. M. Kruijsen, Joost F. Haverman, Henk J. Van Beusekom, Wim Hissink Muller, Marcel J. A. M. Franssen, Dirk-Jan R. A. M. De Rooy, Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial, Arthritis & Rheumatism, 1991, 34, 8
  19. 19
    William S. Wilke, John D. Clough, Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment, Seminars in Arthritis and Rheumatism, 1991, 21, 2, 21

    CrossRef

  20. 20
    R.A. Luqmani, R.G. Palmer, P.A. Bacon, Azathioprine, cyclophosphamide and chlorambucil, Baillière's Clinical Rheumatology, 1990, 4, 3, 595

    CrossRef

  21. 21
    M. J. Wijnands, C. M. Perret, P. L. Van Riel, L. B. Van De Putte, Generalized Urticarial Eruption during Azathioprine Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature, Scandinavian Journal of Rheumatology, 1990, 19, 2, 167

    CrossRef

  22. 22
    P. J. Rooney, W. W. Buchanan, In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?, Clinical Rheumatology, 1990, 9, 3, 315

    CrossRef

  23. 23
    A. A. Drosos, D. Psychos, A. P. Andonopoulos, S. Stefanaki-Nikou, E. B. Tsianos, H. M. Moutsopoulos, Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up, Clinical Rheumatology, 1990, 9, 3, 333

    CrossRef

  24. 24
    Antoine Helewa, Claire Bombardier, Charles H. Goldsmith, Bruce Menchions, Hugh A. Smythe, Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial, Arthritis & Rheumatism, 1989, 32, 12
  25. 25
    Muriel Soden, Jaythoon Hassan, David L. Scott, John G. Hanly, Michael Moriarty, Alex Whelan, Conleth Feighery, Barry Bresnihan, Lymphoid irradiation in intractable rheumatoid arthritis. Long-term followup of patients treated with 750 rads or 2,000 rads, Arthritis & Rheumatism, 1989, 32, 5
  26. 26
    Michael E. Weinblatt, Agnes Lee Maier, Treatment of rheumatoid arthritis, Arthritis & Rheumatism, 1989, 2, 3
  27. 27
    H. Hamdy, R. J. R. McKendry, E. Mierins, J. A. Liver, Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. a twenty-four—week controlled clinical trial, Arthritis & Rheumatism, 1987, 30, 4
  28. 28
    John G. Hanly, Jaythoon Hassan, Michael Moriarty, Ciaran Barry, Jack Molony, Eoin Casey, Alex Whelan, Conleth Feighery, Barry Bresnihan, Lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized study comparing 750-rad treatment with 2,000-rad treatment, Arthritis & Rheumatism, 1986, 29, 1
  29. 29
    Carin E. Dugowson, Bruce C. Gilliland, Management of rheumatoid arthritis, Disease-a-Month, 1986, 32, 1, 1

    CrossRef

  30. 30
    Neil L. Rosenberg, Joseph R. Lacy, Ralph C. Kennaugh, V. Michael Holers, Hans E. Neville, Brian L. Kotzin, Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation, Muscle & Nerve, 1985, 8, 3
  31. 31
    Harold E. Paulus, H. James Williams, John R. Ward, James C. Reading, Marlene J. Egger, Miki L. Coleman, Cecil O. Samuelson, Robert F. Willkens, Maria Guttadauria, Graciela S. Alarcón, Stanley B. Kaplan, Edmund J. Maclaughlin, Arthur Weinstein, Ronald L. Wilder, Marilyn A. Solsky, Robert F. Meenan, Azathioprine versus d-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold, Arthritis & Rheumatism, 1984, 27, 7
  32. 32
    RobinC. Butler, DavidH. Goddard, CONTROVERSY IN THE TREATMENT OF RHEUMATOID ARTHRITIS, The Lancet, 1984, 324, 8397, 278

    CrossRef

  33. 33
    John L. Decker, Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis, The American Journal of Medicine, 1983, 75, 6, 74

    CrossRef

  34. 34
    Lisa Iannuzzi, Neal Dawson, Nazih Zein, Irving Kushner, Does Drug Therapy Slow Radiographic Deterioration in Rheumatoid Arthritis?, New England Journal of Medicine, 1983, 309, 17, 1023

    CrossRef

  35. 35
    Gerald D. Groff, Keith N. Shenberger, William S. Wilke, Thomas H. Taylor, Low dose oral methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature, Seminars in Arthritis and Rheumatism, 1983, 12, 4, 333

    CrossRef

  36. 36
    Elizabeth H. Field, Samuel Strober, Richard T. Hoppe, Andrei Calin, Edgar G. Engleman, Brian L. Kotzin, Amir S. Tanay, H. Jane Calin, Candace P. Terrell, Henry S. Kaplan, Sustained improvement of intractable rheumatoid arthritis after total lymphoid irradiation, Arthritis & Rheumatism, 1983, 26, 8
  37. 37
    P.E. LIPSKY, Advances in Immunopharmacology, 1983,

    CrossRef

  38. 38
    P.E. Lipsky, Biochemical Immunological Pharmacology, 1982,

    CrossRef

  39. 39
    A. Razzaque Ahmed, Ronald Moy, Azathioprine, International Journal of Dermatology, 1981, 20, 7
  40. 40
    Samuel Strober, Brian L. Kotzin, Richard T. Hoppe, Shimon Slavin, Michael Gottlieb, Andrei Calin, Zvi Fuks, Henry S. Kaplan, The treatment of intractable rheumatoid arthritis with lymphoid irradiation, International Journal of Radiation Oncology*Biology*Physics, 1981, 7, 1, 1

    CrossRef

  41. 41
    R. Vinegar, J. F. Truax, J. L. Selph, A. Lea, P. R. Johnston, Azathioprine Treatment of Adjuvant Arthritis, Immunopharmacology and Immunotoxicology, 1979, 1, 4, 497

    CrossRef

  42. 42
    I. L. Dwosh, H. B. Stein, M. B. Urowitz, H. A. Smythe, M. A. Ogryzlo, T. Hunter, Azathioprine in early rheumatoid arthritis, Arthritis & Rheumatism, 1977, 20, 2
  43. 43
    M. BETH MAGGIO-CAVALIERE, LOUIS BONUS, OREN B. GUM, A Dual Approach to the Evaluation of the Efficacy of a New Rheumatoid Arthritic Agent—Pirprofen, The Journal of Clinical Pharmacology, 1976, 16, 1
  44. 44
    Yi-Han Chang, Annual Reports in Medicinal Chemistry Volume 11, 1976,

    CrossRef

  45. 45
    Thomas Hunter, Murray B. Urowitz, Duncan A. Gordon, Hugh A. Smythe, Metro A. Ogryzlo, Azathioprine in rheumatoid arthritis, Arthritis & Rheumatism, 1975, 18, 1
  46. 46
    Rheumatoid arthritis, vasculitis and paroxysmal hypertension, The American Journal of Medicine, 1975, 59, 3, 395

    CrossRef

  47. 47
    Marvin E. Rosenthale, Annual Reports in Medicinal Chemistry Volume 9, 1974,

    CrossRef

  48. 48
    Maria E Suarez-Almazor, Carol Spooner, Elaine Belseck, Azathioprine for treating rheumatoid arthritis, The Cochrane Library,